Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

27%

4 trials in Phase 3/4

Results Transparency

8%

1 of 12 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
6(40.0%)
Phase 2
5(33.3%)
Phase 3
4(26.7%)
15Total
Phase 1(6)
Phase 2(5)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT07568535Phase 3Not Yet Recruiting

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

Role: lead

NCT06325566Phase 3Recruiting

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Role: lead

NCT02412735Phase 3Completed

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

Role: lead

NCT00996073Phase 2Completed

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion

Role: lead

NCT00549913Phase 1Completed

Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)

Role: lead

NCT01106417Phase 1Completed

Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion

Role: lead

NCT01290367Phase 2Completed

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

Role: lead

NCT01851070Phase 2Completed

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

Role: lead

NCT01854567Phase 3Completed

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

Role: lead

NCT01576328Phase 1Completed

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Role: lead

NCT00810212Phase 1Withdrawn

Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion

Role: lead

NCT00721045Phase 2Completed

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

Role: lead

NCT01097486Phase 2Completed

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy

Role: lead

NCT01088191Phase 1Completed

Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

Role: lead

NCT01843387Phase 1Completed

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Role: lead

All 15 trials loaded